Clinical evaluation of the lot-to-lot consistency of an enterovirus 71 vaccine in a commercial-scale phase IV clinical trial
Jinhua Chen,Pengfei Jin,Xiaoqi Chen,Qunying Mao,Fanyue Meng,Xinguo Li,Wei Chen,Meizhi Du,Fan Gao,Pei Liu,Xiujuan Li,Changfu Guo,Tingbo Xie,Weiwei Lu,Qingliang Li,Li Li,Xing Yan,Xiang Guo,Hongqiao Du,Xiuling Li,Kai Duan,Fengcai Zhu
DOI: https://doi.org/10.1080/21645515.2022.2063630
2022-01-01
Human Vaccines & Immunotherapeutics
Abstract:Objective: To evaluate the immunogenicity, safety and lot-to-lot consistency of an inactivated enterovirus 71 (EV71) vaccine cultured in bioreactors with different specifications after full immunization. Methods: A randomized, double-blind trial was performed in 3,000 children aged 6 35 months with six vaccine batches, which were prepared in 40 L and 150 L bioreactors for three consecutive batches respectively. Children were immunized on day 0 and 28, serum samples were collected on day 0 and 56, and neutralizing antibody titers were determined by the microcytopathic method. Immediate reactions were recorded within 30 min, local and systemic symptoms were recorded within 0 similar to 28 days, and serious adverse events were recorded within 6 months. Results: After immunization with two doses of the inactivated EV71 vaccine, the neutralizing antibody GMT was 825.52 +/- 4.09, and the positive conversion rate was 96.18%, with no significant difference. The 95% CI of the serum neutralizing antibody GMT ratio between the two groups after immunization with the three vaccine batches produced in the 150 L and 40 L bioreactors ranged from .67 similar to 1.5. The overall incidence of adverse reactions, mainly grade 1 reactions, for all 6 batches from 0 to 28 days after vaccination was 49.62%, with no significant difference (p = 8736). The incidence of systemic adverse reactions, primarily fever and diarrhea, was 45.14%; the incidence of local adverse reactions, primarily erythema and tenderness, was 9.43%. Conclusion: The EV71 vaccine was highly immunogenic and safe in children aged 6-35 months, and 6 consecutive batches produced by the two bioreactors with different specifications were consistent.